ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
1Q 2025 Total Revenue of 118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of 47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net Income of 171 Million FDA Approved Yield Enhancement Process Anticipated to Provide 20% Production Output Enhancement from Same Starting Plasma Volume, and Support Revenue ...